Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice
https://www.zacks.com/stock/news/2227081/are-you-looking-for-a-top-momentum-pick-why-eyepoint-pharmaceuticals-eypt-is-a-great-choice?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2227081
Feb 15, 2024 - Does EyePoint Pharmaceuticals (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
0
Exelixis (EXEL) Tops Q4 Earnings Estimates
https://www.zacks.com/stock/news/2222066/exelixis-exel-tops-q4-earnings-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2222066
Feb 06, 2024 - Exelixis (EXEL) delivered earnings and revenue surprises of 6.45% and 0.33%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
What Makes EyePoint Pharmaceuticals (EYPT) a Good Fit for 'Trend Investing'
https://www.zacks.com/stock/news/2195361/what-makes-eyepoint-pharmaceuticals-eypt-a-good-fit-for-trend-investing?cid=CS-ZC-FT-tale_of_the_tape|recent_price_strength_screen-2195361
Dec 08, 2023 - If you are looking for stocks that are well positioned to maintain their recent uptrend, EyePoint Pharmaceuticals (EYPT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
0
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
https://www.zacks.com/stock/news/2194725/biotech-stock-roundup-exel-partners-rcus-for-study-phvs-eypt-gain-on-study-data?cid=CS-ZC-FT-analyst_blog|stock_roundup-2194725
Dec 07, 2023 - Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.
0
EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data
https://www.zacks.com/stock/news/2193528/eyepoint-eypt-surges-178-on-upbeat-phase-ii-eye-disease-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193528
Dec 05, 2023 - EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%.
0
Pages: 1
Page 1